Advisers to the U.S. Food and Drug Administration will discuss recommendations for updated COVID-19 vaccines ahead of the ...

Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains. The Investment Committee debate the ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual COVID-19 boosters for ...

Meghan Markle’s Concert Photos Include a Hidden Tribute to Princess Lilibet Stephen Colbert Loves His Audience's Reaction To ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.